IL6 and inflammatory bowel disease: Janus kinase (JAK) is critical for the transmission of cytokine types, in which JAK2 is involved in the signaling of IL-6, iNF-γ, etc. JAK inhibitors are approved by the FDA for IBD treatment currently [37].